Investigating the role of a specific protein in lung fibrosis related to scleroderma
Official title: The role of BHLHB2 in Scleroderma-Associated Lung Fibrosis
Funded at Medical University of South Carolina · NIH-10899503 · Data updated 2026-11-12
This study is looking at how a protein called BHLHB2 affects lung scarring in people with scleroderma, hoping to find new ways to help treat lung problems caused by this condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $53,880 |
| NIH project number | 5F31HL170551-02 |
| Project ID | NIH-10899503 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with scleroderma who are experiencing lung fibrosis.
✕Less likely to help
Patients with lung fibrosis not related to scleroderma may not benefit from this research.
What this research studies
This research focuses on understanding how the protein BHLHB2 contributes to lung fibrosis in patients with scleroderma, a serious autoimmune disease. The study examines the relationship between inflammatory signals and the production of fibrotic factors in lung cells. By analyzing how these factors interact, researchers aim to identify potential new targets for treatment. Patients may benefit from insights that could lead to more effective therapies for pulmonary fibrosis associated with scleroderma.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients suffering from lung fibrosis due to scleroderma.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in fibrotic diseases, suggesting potential for success in this approach.
Where this research is happening
-
Medical University of South Carolina
Charleston, United States Active
Researchers
- Principal investigator: Adewale, Adegboyega Timothy — Medical University of South Carolina
- Study coordinator: Adewale, Adegboyega Timothy
Related research
Other NIH-funded projects on the same topics.
-
Lymphatic ERG signaling and fibrosis in scleroderma
This grant explores how a key gene pathway involved in lymphatic vessels may contribute to fibrosis in scleroderma, with the goal of finding new targets to improve vascular health and tissue healing.
-
New mouse and human lung models to study how T cells drive scleroderma-related lung fibrosis
Aims to understand how specific T cell types contribute to lung scarring in scleroderma by using advanced mouse and human lung models.
-
Investigating lymphatic signaling in scleroderma fibrosis
This study is looking at how certain signals in the lymphatic system might affect people with scleroderma, with the goal of finding new ways to improve treatments for this condition.
-
New treatment for lung fibrosis related to scleroderma
This study is looking at a new treatment made from collagen that could help people with lung fibrosis caused by scleroderma, aiming to improve their health and quality of life more effectively than current options.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.